Daily News

Daily News

Epigallocatechin gallate (EGCG) reverses gemcitabine-resistant gastric cancer

Gene Therapy Daily News

2020 JUN 24 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Daily News -- Fresh data on Oncology - Gastric Cancer are presented in a new report. According to news originating from Changchun, People’s Republic of China, by NewsRx correspondents, research stated, “Epigallocatechin gallate (EGCG), as one of the main ingredients of green tea, has been reported to have potential prevention on a variety of solid tumors. However, the system-wide molecular mechanisms targeted of EGCG’s anti-tumor effect has not been illustrated.”

Our news journalists obtained a quote from the research from Northeast Normal University, “Here, AGS and SGC7901 GC cells were used to investigate the EGCG-mediated change of gene expression. Our data showed that EGCG retarded cell growth and promoted cell death of GC in dose-dependent manner. Analyses based on transcription, translation as well as function was performed explore the elusive anticancer role of EGCG. Of them, cell cycle was probably implicated key pathway of EGCG. Besides, our data revealed numerous LncRNAs activated after EGCG treatment. In this study, LINC00511 was discovered to be suppressed by EGCG and highly expressed in GC cells and tissues. What is more, enhanced level of LINC00511 was demonstrated in GC I/II along with III/IV stages. Knockdown of LINC00511 inhibited cell growth but promoted cell death ratio in GC. Additionally, our data suggested LINC0051 could decrease the expression of miR-29b, followed by inducing GC development. Knockdown of miR-29b recovered the effects of LINC00511 silencing. In addition, we found overexpression of KDM2A, a target of miR-29b, would rescue level of LINC00511.”

According to the news editors, the research concluded: “All the data showed that the LINC00511/miR-29b/KDM2A axis can be used as a diagnostic and therapeutic target for GC.”

For more information on this research see: Epigallocatechin gallate reverses gemcitabine-resistant gastric cancer by regulating the long noncoding RNA LINC00511/miR-29b/KDM2A axis. Biochimica Et Biophysica Acta, 2020;():165856. Biochimica Et Biophysica Acta can be contacted at: Elsevier Science BV, PO Box 211, 1000 AE Amsterdam, Netherlands.

The news correspondents report that additional information may be obtained from X. Chen, Key Laboratory of Molecular Epigenetics of the Ministry of Education, Northeast Normal University, Changchun 130024, People’s Republic of China. Additional authors for this research include Y. Zhao, J. Jiang, X. Wan, Y. Wang and P. Xu.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.bbadis.2020.165856. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

The publisher’s contact information for the journal Biochimica Et Biophysica Acta is: Elsevier Science BV, PO Box 211, 1000 AE Amsterdam, Netherlands.

(Our reports deliver fact-based news of research and discoveries from around the world.)